EBS — Emergent BioSolutions Inc. · 2026-09-07 · Verdict: WATCH · Conviction 2

Price $6.21 (screen row close, universe_under2b.csv refreshed 2026-09-07; no live quotes available) · Mkt cap $318M on 51.3M shares · EV about $768M · EV/EBIT 7.6x on CY2025 EBIT of $100.1M · FCF yield 49% on CY2025 but about 25% trailing · Net debt $450.0M · ADV $7.1M Sources read: 10-K 2026-02-27 (Items 1, 1A, 7), 10-Q 2026-08-06, DEF 14A 2026-03-20, 8-Ks of 2026-04-17, 04-30, 06-29, 08-05 (with the Q2 release and slides) and 09-01, Form 4s (12 of 46, per meta.json). No analyst Q&A transcript was in the pack.

1. What the business actually does

Emergent sells medical countermeasures, almost all to one buyer. The MCM segment covers anthrax (BioThrax, CYFENDUS, ANTHRASIL), smallpox and mpox (ACAM2000, TEMBEXA, CNJ-016), botulism (BAT) and Ebola (Ebanga), sold mainly to the US government for the Strategic National Stockpile under fixed-price contracts with annual options; BAT, CNJ-016 and ANTHRASIL are each the only FDA-licensed product of their kind (10-K 2025, Item 1 and Competition). The Commercial segment is NARCAN and KLOXXADO naloxone sprays against four approved generics.

2. Why it is mispriced, and the honest answer

The screen row is stale, and that is most of the apparent cheapness. On 5 August management cut FY2026 guidance from $720-760M revenue and $155-175M adjusted EBITDA to $645-675M and $130-150M (8-K 2026-08-05, slide 19). Since H1 2026 already delivered $132.0M of adjusted EBITDA on $390.4M of revenue, the revised guide implies second-half revenue of $255M-$285M, down 25% to 33% against H2 2025's $380M, and second-half adjusted EBITDA between minus $2M and plus $18M. Cash followed: H1 operating cash flow was $22.3M against $95.2M a year earlier (10-Q Q2 2026), so trailing FCF is roughly $81M, not $156.8M. The edge case is real: post-restructuring, with forced selling after a 50% fall from December's $12.36 close. But on current numbers the discount is not obviously excessive. I do not think the market is wrong; I think it is early.

3. Unit economics and growth

Naloxone fell 43% to $226.1M in 2025 on generic pressure (10-K 2025, Item 7), then 22% again to $52.4M in Q2 2026, with segment gross margin down 19 points to 13% and gross profit of $6.7M (10-Q Q2 2026). Management wrote off $191.3M of the NARCAN intangible in Q2 and guides to a further 20-25% commercial decline; at 13% margin this leg contributes almost nothing.

MCM is the company: $168.0M of Q2's $234.3M revenue at 64% gross margin. But the quarter was timing, with Smallpox up 150% to $101.6M and Other Products up from $6.2M to $54.1M, both attributed in the filing to order timing. The structural read is worse: ACAM2000 annual option exercises ran $176.0M (2020), $182.2M (2021), none in 2022, $120.0M (2023), $99.9M (2024), $56.0M (2025), a 53% three-year decline on the largest contract, with three of nine option years unexercised (10-K 2025, Item 1). MCM is guided flat to slightly down, and with international at 20% of H1 MCM revenue the USG is roughly 55% of the company on my arithmetic.

4. Balance sheet and capital allocation

$589.7M of debt against $139.7M of cash, so $450.0M net debt at 1.9x trailing leverage (8-K 2026-08-05, slide 30): $439.7M of 3.875% notes due 2028 plus a $150M OrbiMed term loan taken in April 2026 at SOFR plus 6.25%, maturing 2031 (10-K 2025, Item 1A; 8-K 2026-04-17). That refinancing cost a $20.5M extinguishment loss and roughly tripled the tranche's marginal rate. The 2028 notes are the wall: refinancing $439.7M near the OrbiMed rate adds $25-30M of annual interest against guided FY2026 interest of about $40M, and the term loan springs to 2028 if they are not dealt with. Its 5.25x covenant is first tested 30 September 2026; year-end gross leverage near 4.2x passes, but another cut of August's size would not leave much. Capital allocation is rational: $43.3M of buybacks since March 2025 took shares to 51.3M, and an August authorization allows $75.0M of note repurchases. Insiders bought nothing in twelve months; four directors sold 61,925 shares within two days of the 30 April grant (form4_last12m.csv).

5. Management: what they said versus what they did

Guidance was affirmed on 30 April and cut on 5 August. Joe Papa's release calls Q2 a beat while conceding "we are at a critical juncture in our turnaround, primarily stemming from our naloxone business" (8-K 2026-08-05). The proxy is the sharper tell: the 2023-2025 PSUs missed threshold on both cumulative revenue and adjusted EBITDA margin (12.9% against 13.0%) and the committee used upward discretion to pay 25% anyway; say-on-pay fell from a five-year average of 91% to 84% (DEF 14A 2026). Papa holds an $8M incentive contingent on a $15 share price by March 2029.

6. Valuation

Base: 2027 adjusted EBITDA of $150M (the guided $140M FY2026 midpoint plus $40M of restructuring savings, less $15M of further naloxone erosion, no MCM recovery) at 5.5x, less $420M net debt, is $7.90, up 27%. Bear: $110M as MCM timing reverses and options keep shrinking, at 4.5x less $430M net debt, is about $1.25; the downside is near total. Bull: $185M as cost cuts land in full and naloxone stabilizes, at 6.5x less $400M net debt, is $15.60. Weighting 40/30/30 gives about $8.00, not enough premium for a distribution that wide. Reverse DCF: at $6.21 the $768M enterprise against roughly $108M of 2026 unlevered cash flow (guided $140M EBITDA less $17M capex and $15M cash taxes) implies a 14% perpetual unlevered return at zero growth, or a 4% annual decline forever at a 10% discount rate. That is slow melt priced, not distress, and it looks about right.

7. Catalysts and timeline

The Q3 print in early November is the thesis: the $110-130M revenue guide, the first covenant measurement at 30 September, and whether H2 adjusted EBITDA is really near zero. Restructuring charges of $10.0-11.5M land in Q3 and Q4 with the savings following (10-Q Q2 2026), and the seventh of nine ACAM2000 options remains unannounced.

8. Kill criteria

1. FY2026 adjusted EBITDA below the $130M low end, or Q3 revenue below $110M.
2. Reported leverage above 4.75x at any quarter end, or any covenant waiver. The 10-K already warns the company "may be unable to comply with debt covenants in future periods without additional sources of liquidity" (Item 1A).
3. The seventh ACAM2000 option skipped, or exercised below $50M.
4. Common equity drawn on the $250M shelf, or buybacks halted while the notes stay unrepurchased.

9. Verdict and summary

WATCH, conviction 2. Emergent screens at 7.6x EV/EBIT on a 49% free cash flow yield, and both are artifacts of a CY2025 that no longer describes it: the 5 August guidance cut leaves a second half generating between minus $2M and plus $18M of adjusted EBITDA on revenue down 25% to 33%, and trailing free cash flow has already halved. Naloxone now earns a 13% gross margin and just took a $191.3M write-off, while the MCM leg that carries the company shows its largest contract's option value falling from $120.0M in 2023 to $56.0M in 2025, against $589.7M of debt whose 3.875% notes must be refinanced by 2028 at perhaps three times the coupon. It is not a pass because the products are sole-source, the $40M of savings is dated and specific, management is buying back stock and discounted notes, and at 5.5x forward EBITDA a levered stub does not need much to double. But the bear case is close to zero, so the Q3 print settles it.

Research for discussion, not investment advice. Positions and sizing are the reader's decision.